The invention relates to substituted polycyclic aryl and heteroaryl
tertiary-heteroalkylamine compounds useful as inhibitors of cholesteryl
ester transfer protein (CETP; plasma lipid transfer protein-I) and
compounds, compositions and methods for treating atherosclerosis and other
coronary artery diseases. Preferred tertiary-heteroalkylamine compounds
are substituted N,N-disubstituted non-fused heterocyclo amines. A
preferred specific N,N-disubstituted non-fused heterocyclo amine is the
compound:
##STR1##